{Reference Type}: Journal Article
{Title}: [Risk management with regard to QT-prolonging drugs].
{Author}: Aengevaeren VL;van Gastel MDA;Fleuren HWHA;Helsloot I;Beukema RJ;Kramers C;
{Journal}: Ned Tijdschr Geneeskd
{Volume}: 168
{Issue}: 0
{Year}: 2024 Jun 19
暂无{Abstract}: Drug-induced QT prolongation increases the risk of Torsade de Pointes (TdP). Drug-induced QT prolongation is a complex and unpredictable system due to many uncertainties. Risk factors such as electrolyte disturbances, heart failure and genetics play an important role in estimating the effect on QT prolongation. Moreover, the degree of QT prolongation is not always directly related to the risk of TdP and the assessment of the QT-interval is variable depending on the type and timing of QT measurement. Therefore, the variation in QT measurement may be larger than the effect of certain drugs on the QT interval. Because of the potentially lethal risk, several measures are undertaken to reduce the risk of QT prolongation and TdP, while their effect and proportionality are unclear. We suggest we should be less stringent in certain settings when risk of TdP is extremely low given the limited availability of our resources.